Evidence map›Paper›PMID 41615623›Full record

ArticleDrug delivery and translational research2026

From bench to bulk: exploring in-line homogenization for scale-up and continuous production of vesicular systems.

Kshitija M Phatak, Ankita N Yawalkar, Pradeep R Vavia

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kshitija M Phatak *Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, University under Section 3, of UGC Act - 1956, Elite Status and Center of Excellence - Govt. of Maharashtra, N. P. Marg, Matunga (E), Mumbai, Maharashtra, 400019, India.
Ankita N Yawalkar *Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, University under Section 3, of UGC Act - 1956, Elite Status and Center of Excellence - Govt. of Maharashtra, N. P. Marg, Matunga (E), Mumbai, Maharashtra, 400019, India.
Pradeep R VaviaDepartment of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, University under Section 3, of UGC Act - 1956, Elite Status and Center of Excellence - Govt. of Maharashtra, N. P. Marg, Matunga (E), Mumbai, Maharashtra, 400019, India. pr.vavia@ictmumbai.edu.in.ORCID http://orcid.org/0000-0001-8568-7857

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanovesicular systems hold a significant promise for drug delivery, yet their clinical translation is hindered by challenges in scalability and reproducibility. This study introduces in-line homogenization as a continuous, organic solvent-free approach for scalable fabrication of bilayered unilamellar vesicles, NioTherms (Niosome-like) and ThermoSomes (Liposome-like), loaded with model hydrophobic (Posaconazole, PCZ) and hydrophilic (Dexamethasone Sodium Phosphate, DEX) drugs. Using a heat-mixing method as the baseline, formulations were scaled from 10 mL (1x) to 1 L (100x) via a rotor-stator-based in-line homogenizer. Process parameters including pump speed, homogenizer speed, cycle number, phase ratio and output rate were optimized. The resulting vesicles exhibited uniform particle size and entrapment efficiencies comparable to the lab-scale batches. The formation of vesicles, morphology, internal structure, and integrity of the formed particles was confirmed by TEM and SANS analysis. The system enabled rapid batch processing (< 5 min for 1 L) with substantial product yields up to 80%. The process demonstrated excellent reproducibility and eliminated the need for post-processing. This study establishes in-line homogenization as a robust, scalable platform for faster production of nanovesicular drug delivery systems, effectively bridging the gap between bench-scale development and continuous manufacturing.

Indexed as

DexamethasoneTriazolesUnilamellar LiposomesDrug CompoundingHydrophobic and Hydrophilic InteractionsLiposomesParticle SizeDexamethasonedexamethasone 21-phosphateLiposomesTriazolesUnilamellar LiposomesContinuous productionIn-line homogenizerNanoformulationsPilot scaleScale-upVesicular system

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.